U.S. Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines, Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A, Influenza Virus Type B), by Age Group (Pediatrics, Adults) is estimated to be valued at US$ 3,975.7 Million in 2022 and is expected to exhibit a CAGR of 16.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing adoption of inorganic strategies such as product approval by key market players is expected to drive the U.S. influenza vaccines market growth over the forecast period. For instance, in October 2021, Seqirus USA Inc., a pharmaceutical company, announced that they had received an approval from U.S Food and Drug Administration for flucelvax quadrivalent influenza vaccine, which is the first cell-based influenza vaccine in U.S. for children as young as six months old.
U.S. Influenza Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the U.S. influenza vaccines market, owing to the increasing research and development of influenza vaccines. For instance, in October 2022, Novavax, a biotechnology company, announced that they had developed COVID-19-influenza combination (CIC) vaccine candidate including both antibody and polyfunctional CD4+ T-cell to produce immune responses against COVID-19 and homologous and heterologous influenza strains.
U.S. Influenza Vaccines Market: Key Developments
In September 2022, Merck & Co., Inc., a pharmaceutical company, started a clinical trial to study the evaluation of safety, tolerability, and immunogenicity of V116 when administered concomitantly with quadrivalent influenza vaccine (QIV) in adults 50 years of age or older. This trial is expected to complete in July 2023.
Browse 9 Market Data Tables and 14 Figures spread through 160 Pages and in-depth TOC on “U.S. Influenza Vaccines Market”- Forecast to 2030, U.S. Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines, Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A, Influenza Virus Type B), by Age Group (Pediatrics, Adults)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-influenza-vaccines-market-1127
Moreover, increasing availability of influenza vaccines in U.S. is expected to drive the U.S. influenza vaccines market over the forecast period. For instance, in July 2020, Seqirus USA Inc., a pharmaceutical company, announced that they had shipped influenza vaccines to the U.S. customers for 2020/21 influenza season. As, the Centers for Disease Control and Prevention (CDC) recommends every six months and older to receive an annual influenza vaccine without contraindication to prevent seasonal influenza.
Key Takeaways of the U.S. Influenza Vaccines Market:
- The U.S. influenza vaccines market is expected to exhibit a CAGR of 16.3% during the forecast period due to the ongoing research and development by the key market players. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a biotechnology company, started a clinical trial in U.S. to evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil, an antiviral drug for the treatment of influenza in healthy pediatric participants from birth to <1 year with influenza like symptoms. This trial is expected to complete in August 2023
- Among vaccine type, quadrivalent vaccines segment is estimated to hold a dominant position in the U.S. influenza vaccines market due to adoption of inorganic strategies such as product approval by key market players over the forecast period. For instance, in October 2018, Seqirus USA Inc., a pharmaceutical company, announced that they had received an approval from U.S Food and Drug Administration for afluria quadrivalent influenza vaccines for children of six months in U.S., who have more risk for getting the flu due to their weaker immune systems. It is presented in pre-filled syringes as well as multi-dose vials in the U.S.
Major players operating in the U.S. influenza vaccines market include Seqirus USA Inc., GSK plc., Sanofi, Pfizer Inc., AstraZeneca, Novartis AG, Merck & Co., Inc., Protein Sciences Corporation, Moderna, Inc., INOVIO Pharmaceuticals, Novavax and EMERGENT
